SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

SHEL.UK

2,976

+0.42%↑

BP

470.6

-0.81%↓

Search

Smith & Nephew PLC

Deschisă

1,328 -0.6

Rezumat

Modificarea prețului

24h

Curent

Minim

1323

Maxim

1350.5

Indicatori cheie

By Trading Economics

Venit

296M

Vânzări

3B

P/E

Medie Sector

32.354

48.535

EPS

0.429

Randament dividend

2.89

Marjă de profit

9.895

Angajați

17,000

EBITDA

723M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+11.53% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.89%

3.96%

Următoarele câștiguri

2 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

11B

Deschiderea anterioară

1328.6

Închiderea anterioară

1328

Smith & Nephew PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 feb. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb. 2026, 22:36 UTC

Câștiguri

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb. 2026, 22:32 UTC

Câștiguri

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb. 2026, 23:58 UTC

Market Talk
Câștiguri

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb. 2026, 23:58 UTC

Market Talk
Câștiguri

Global Energy Roundup: Market Talk

23 feb. 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb. 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb. 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb. 2026, 23:39 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb. 2026, 23:31 UTC

Câștiguri

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb. 2026, 23:31 UTC

Câștiguri

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb. 2026, 23:27 UTC

Câștiguri

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb. 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb. 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb. 2026, 22:31 UTC

Câștiguri

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb. 2026, 22:24 UTC

Câștiguri

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb. 2026, 22:21 UTC

Câștiguri

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb. 2026, 22:21 UTC

Câștiguri

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb. 2026, 22:20 UTC

Câștiguri

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparație

Modificare preț

Smith & Nephew PLC Așteptări

Obiectiv de preț

By TipRanks

11.53% sus

Prognoză pe 12 luni

Medie 1,490.57 GBX  11.53%

Maxim 1,650 GBX

Minim 1,290 GBX

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSmith & Nephew PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

7 ratings

5

Cumpărare

2

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat